Strad Polyclonal Antibody

STE20-related kinase adapter protein alpha encoded by STRADA contains a STE20-like kinase domain, but lacks several residues that are critical for catalytic activity, so it is termed a 'pseudokinase'. STE20-related kinase adapter protein alpha forms a heterotrimeric complex with serine/threonine kinase 11 (STK11, also known as LKB1) and the scaffolding protein calcium binding protein 39 (CAB39, also known as MO25) . The protein activates STK11 leading to the phosphorylation of both proteins and excluding STK11 from the nucleus. The protein is necessary for STK11-induced G1 cell cycle arrest. A mutation in this gene has been shown to result in polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome. Multiple transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their full-length nature is not known.

STRADA; LYK5; STRAD; STE20-related kinase adapter protein alpha; STRAD alpha; STE20-related adapter protein; Serologically defined breast cancer antigen NY-BR-96

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:10000; IF 1:50-200

STRADA; LYK5; STRAD; STE20-related kinase adapter protein alpha; STRAD alpha; STE20-related adapter protein; Serologically defined breast cancer antigen NY-BR-96